Under the contract, TPP and the University of Aberdeen expect to work on the commercialization opportunities in the areas of nervous system disorders, immunology/inflammation and oncology.
University of Aberdeen Kosterlitz Centre for Therapeutics Operations head Iain Greig said the collaboration will be of enormous value in taking forward the biomedical discoveries made at the University of Aberdeen’s Kosterlitz Centre.
Kosterlitz Centre director Ruth Ross said the agreement with TPP will provide them with a mechanism whereby we can convert our discoveries into valuable new medicines of the future.
The term of the agreement can be extended in the future.